X
Chinese pharma market primed for growth after sweeping reforms
https://pharmaphorum.com/r-d/views-analysis-r-d/chinese-pharma-market/
CAR T
Allogene raises another $120m to develop ‘off-the-shelf’ CAR-Ts
Startup biotech already raised $300m earlier this year
NHS to fund Novartis’ CAR-T therapy Kymriah
Decision comes after NICE’s knock-back for Gilead’s rival
Regeneron forges CAR-T R&D partnership with bluebird bio
Deal combines Regeneron’s receptor tech with CAR-T biotech’s expertise
Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research
Challenges facing Immuno-Oncology industry
Gilead develops solid tumour cell therapy with Gadeta
Gilead has option to buy biotech if things go well
